Bile duct cancer trial halted after just one patient
NCT ID NCT06739252
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and improve survival. However, the study was terminated early after enrolling only one participant, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, oxaliplatin, 5-fluorouracil, atezolizumab, bevacizumab, capecitabine, tegafur
What this could lead to
If successful, this approach could improve surgical outcomes and reduce recurrence for patients with high-risk bile duct cancer.
What could go wrong
The trial was terminated early with only 1 participant, so results are not reliable. The combination also carries risks like immune-related side effects and liver toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China